Federal Register #E1832024

NIH/NIA Licensing and Co-Development Opportunity for Novel Anti-Inflammatory Therapeutic Compounds

This opportunity from the National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), seeks partners for licensing and research co-development of novel anti-inflammatory therapeutic compounds. - Government Buyer: - National Institutes of Health (NIH) - National Institute on Aging (NIA) - Technology Transfer Center, National Cancer Institute - OEMs/Inventors: - National Institute on Aging (NIA) - National Institutes of Health (NIH) - Products/Technologies Requested: - 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones (part number: E1512022) - Pre-clinical therapeutic compounds with potent anti-inflammatory properties - Patent pending (US 19/102,830) - Novel IMiD Analogs with Enhanced Stability and Solubility (part number: E1832024) - Do not bind cereblon protein, reducing teratogenicity - Patent application (PCT/US2025/034951) - Services Requested: - Research co-development and licensing for pre-clinical and clinical development of these compounds - Unique/Notable Requirements: - Compounds are designed for systemic degenerative and neurodegenerative disorders, including inflammatory, autoimmune diseases, viral infections, and cancer - Improved chemical stability, water solubility, and safety profile compared to classic IMiDs (e.g., thalidomide, lenalidomide, pomalidomide) - Opportunity is for licensing and collaborative research, not direct product procurement - No specific commercial vendors or product part numbers beyond the government-owned inventions

Description

The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of novel thalidomide analog compounds as anti-inflammatory therapeutics. These compounds are intended to treat systemic degenerative and neurodegenerative disorders by reducing inflammation without the teratogenic effects associated with classic immunomodulatory imide drugs (IMiDs). The compounds demonstrate improved chemical stability, enhanced water solubility, and potent anti-inflammatory properties, with potential applications in neurodegenerative diseases, inflammatory disorders, autoimmune disorders, viral infections, and cancer.

View original listing